This trial will evaluate the safety and efficacy of a reduced intensity allogeneic HSCT from partially HLA-mismatched first-degree relatives utilizing PBSC as the stem cell source. The primary objective of the study is to estimate the incidence of graft rejection and acute GVHD. A secondary objective will be to estimate the incidence of the relapse, NRM, OS, chronic GVHD and EFS.
Patients will receive a haploidentical transpalnt using a fludarabine melphalan prepartive regimen. Patients will get cyclophosphamide on days 3 \& 4 post-transplant.
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
TREATMENT
Masking
NONE
Enrollment
25
fludarabine (30mg/m2) given every day starting on Day -6 through Day -2;
cyclophosphamide (50mg/kg) given every day starting on Day 3 through Day 4.
Northside Hospital
Atlanta, Georgia, United States
Graft Rejection
Measurement of donor cells vs. recipient cells
Time frame: 100 days
Overall Survival
Number of participants still alive 2 years after transplant
Time frame: 2 years
Relapse Incidence
Number of patients with disease reoccurrence at 1 and 2 years post-transplant
Time frame: 2 years
GVHD Incidence
The number of participants that developed graft-versus-host-disease before or at 100 days after transplant
Time frame: 100 days
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.